LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 3, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Rockwell Medical, Inc. (“Rockwell Medical” or the “Company”) (NASDAQ: RMTI) securities between September 9, 2015 through February 29, 2016, inclusive (the “Class Period”). Rockwell Medical investors have until May 3, 2016 to file a lead plaintiff motion.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the primary product offering for Triferic will be in a powder packet packaging, which the FDA has not yet approved; (2) Rockwell Medical is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement; and (3) as a result, defendants’ statements about Rockwell Medical’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Following the Company’s most recent earnings call, analysts questioned the commercial viability of Triferic despite the Company’s prior predictions regarding Triferic’s future performance. As a result, the Company’s shares sharply declined in value, thereby damaging investors.
If you purchased Rockwell Medical shares during the Class Period, you may move the Court no later than May 3, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.